<PAGE>
OMB Approval
OMB Number: 3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response: 14.90
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
FEMINIQUE CORP.
(formerly Biopharmaceutics, Inc.)
---------------------------------------------------
Name of Issuer
COMMON STOCK
---------------------------------------------------
Title of Class of Securities
090646-10-0
---------------------------------------------------
CUSIP No.
JOHN FIGLIOLINI
201 E. 80th Street, Apartment 10-F
New York, New York 10021
212-794-1877
----------------------------------------------------
Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications
January 6, 2000
----------------------------------------------------
Date of Event Which Requires Filing of this Statement
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule
13d-1(b)(3) or (4), check the following box: ______
SCHEDULE 13D/A
CUSIP No. 090646-10-0
Page 2 of 3 Pages
1. Name of Reporting Person
JOHN P. FIGLIOLINI
2. Check the appropriate box if a member of a Group:
(A)
(B) X
3. SEC USE ONLY
4. SOURCE OF FUNDS
WC/PF/AF
5. Check box if disclosure of legal proceedings is required
pursuant to items 2(d) or 2 (e):
Not applicable.
6. Citizenship or place of organization:
USA
7. Sole Voting Power:
Yes - 2,131,137 Shares
8. Shared Voting Power:
Yes - 3,333,333 Shares
9. Sole Dispositive Power:
Yes - 2,131,137Shares
10. Shared Dispositive Power:
Yes - 3,333,333 Shares
11. Aggregate Amount Beneficially owned by Each Reporting Person
5,464,470 Shares
Page 3 of 3 Pages
12. Check box if the aggregate amount in row (11) excludes
certain shares:
Not applicable.
13. Percent of Class represented by amount in Row (11).
24%
14. Type of Reporting Person
EP/CO/IN/OO
ITEM 1. SECURITY AND ISSUER
This statement relates to the common stock, $.001 of Feminique
Corp. (formerly Biopharmaceutics, Inc.,), a Delaware Corporation
(the "Company"). The Company's principal executive offices are
located at 990 Station Road, Bellport, New York.
ITEM 2. IDENTITY AND BACKGROUND
111,000 Shares - Berkshire International Finance, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Berkshire is an Investment Banking firm owned by 100% by John P.
Figliolini.
275,000 - Phillip Louis Trading, Inc.
(formerly European Equity Partners, Inc.)
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Phillip Louis Trading, Inc. is a registered broker/dealer owned
100% by John P. Figliolini.
26,116 Shares - Medical Technologies, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Medical Technologies, Inc. is a holding Company owned 100% by
John P. Figliolini.
135,246 Shares - Histon Financial Services, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Histon Financial Services, Inc. is owned 100% by John P.
Figliolini.
33,725 Shares - Berkshire International Finance, Inc.
Pension and Profit Sharing Account
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
1,513,050 Shares - John P. Figliolini
201 E. 80th Street, Apt. 10-F
New York, New York 10021
15,000 Shares - Sierra Growth & Opportunity, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Sierra is owned 100% by John P. Figliolini.
22,000 Shares - Utopia Capital, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Utopia Capital, Inc. is owned 100% by John P. Figliolini.
3,333,333 Shares - Dynamic Corporate Holdings Corporation
Dynamic Corporate Holdings Corporation is British Virgin Islands
corporation of which John P. Figliolini is a 50% owner.
Mr. Figliolini is a registered rep and investment banker. During
the last five years, the Reporting Individual has not been
convicted in a criminal proceeding (excluding traffic violations
or similar misdemeanors) nor been a party to a civil proceeding
of a judicial or administrative body of competent jurisdiction
resulting in him being subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating
activities subject to federal or state securities laws or finding
any violations with respect to such laws. The Reporting
Individual is a United States citizen.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
The source of funds used in making purchases of 4,535,624 shares
was from working capital and personal funds. No monetary
compensation was paid to the Company by the Reporting Individual
for 827,000 shares. These shares were issued to the Reporting
Individual by the Company as compensation to the Reporting
Individual for finder fees and financing fees performed for the
Company. 101,846 shares were issued to the Reporting Individual
in satisfaction of a debt owed to him in the amount of
$18,332.28.
ITEM 4. PURPOSE OF TRANSACTION
The purpose of the acquisition of the common stock is to make a
speculative investment and in order to provide consulting
services and financing services to the Company relating to past
acquisition and financings and future acquisitions and financing.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
According to information supplied to the Reporting Individual by
the Company, the number of shares of common stock outstanding as
of March 31, 1999 is 22,755,399. Accordingly, the Reporting
Individual is the beneficial owner of 5,464,470 shares which is
24% of the outstanding common stock calculated in accordance
with Rule 13-D-3(d)(i). The Reporting Individual will have sole
voting and dispositive power with respect to 2,131,137 shares and
shared voting and dispositive power with respect to 3,333,333
shares.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS
WITH RESPECT TO SECURITIES OF THE ISSUER.
Other than the purchase of these shares, there are no other
contracts, arrangements, understandings or relationships (legal
or otherwise) between the Reporting Individual and any other
person with respect to any securities of the Company, including
but not limited to, transfer or voting of any of the securities
of the Company, finder's fees, joint ventures, loan or option
arrangements, puts or calls guarantee of profits, division of
profits and loss, or the withholding of proxies.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
None.
Dated: January 20, 2000 /S/ JOHN P. FIGLIOLINI
------------------------
JOHN P. FIGLIOLINI
